Background Children undergoing cardiac surgery may exhibit a pronounced inflammatory response to cardiopulmonary bypass (CPB). Inflammation is recognized as an important pathophysiologic process leading to acute kidney injury (AKI). The aim of this study was to evaluate the association of the inflammatory cytokines interleukin (IL)-6 and IL-10 with AKI and other adverse outcomes in children after CPB surgery. Methods This is a sub-study of the Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI)
Introduction
Pediatric acute kidney injury (AKI) has become a significant health concern due to its rising incidence [1, 2] . AKI develops in about 50 % of children who undergo cardiac surgery with cardiopulmonary bypass (CPB) [3, 4] . Pediatric AKI is associated with adverse outcomes, such as higher mortality and longer length of hospital stay [5] . In addition, clinical studies have shown that pediatric AKI may be associated with higher risk of developing proteinuria, hypertension, and chronic kidney disease in the long term [6, 7] .
Serum creatinine is currently used to diagnose AKI in children. It is a useful indicator of glomerular clearance but is a late marker of AKI and is not involved in the process of AKI. Novel AKI biomarker candidates currently being evaluated include some of the cytokines that mediate inflammation. In the pathophysiologic context, these are relevant as AKI is an inflammatory process mediated by a number of cytokines [8] . Two cytokines that are believed to play a role in the pathophysiology of AKI are interleukin (IL)-6 and IL-10. IL-6 is one of the main pro-inflammatory cytokines, while IL-10 has antiinflammatory and immunomodulatory functions related to the regulation of lymphocyte activity. Studies in children and adults have demonstrated that these cytokines may be potential biomarkers of AKI [9] [10] [11] [12] , and those using animal models have shown that AKI itself, not just the pro-inflammatory state of sepsis or CPB, induces higher IL-6 and IL-10 levels [13, 14] .
IL-6 and IL-10 are also known to play a key role in the systemic inflammatory response to cardiac surgery and CPB [15] . This heightened state of inflammation is partly due to surgical trauma, including sternotomy and incision into the myocardium. Most of the pro-inflammatory response is elicited as the patient's blood contacts the extracorporeal circuit, leading to cytokine production, endothelial dysfunction, and neutrophil, platelet, and complement system activation [16] . There is evidence that these circulating cytokines and activated cells cause organ dysfunction, particularly in the kidneys [17] . Children are especially vulnerable to this inflammatory state as a greater percentage of their blood is exposed to the artificial circuit, leading to a more pronounced inflammatory response [18] . There is a paucity of data in children on these inflammatory biomarkers and their role in clinical AKI. Hence, we conducted an analysis of perioperative plasma IL-6 and IL-10 concentrations as part of the TRIBE-AKI (Translational Research Investigating Endpoints in Acute Kidney Injury) prospective multicenter cohort of children undergoing cardiac surgery. Our goal was to assess whether these two cytokines are associated with AKI or other adverse patient outcomes.
Methods
This is a sub-study of the TRIBE-AKI cohort in which children who were undergoing surgery for congenital heart disease were prospectively enrolled. Patients were enrolled from July 2007 to December 2010 at three medical centers within the TRIBE-AKI network [3] .
The TRIBE-AKI parent study included patients older than 1 month and younger than 18 years who were scheduled to be placed on CPB during cardiac surgery. We excluded patients who had a history of kidney transplantation or prior receipt of dialysis. Written informed consent was obtained from all parents or legal guardians, along with an assent when appropriate. The study was approved by each center's research ethics board. Patients were only included in this sub-study if blood specimens were collected on all consecutive days after surgery. IL-6 and IL-10 were selected as candidate biomarkers of AKI by a literature review of inflammatory mediators that have reported associations with AKI. The reporting of this study follows guidelines set out in the Strengthening the Reporting of Observational Studies in Epidemiology statement [19] .
Sample collection
Blood specimens were collected preoperatively and postoperatively on three consecutive days after surgery in the parent study. The first postoperative blood sample was collected 0-6 h after admission to the intensive care unit (ICU) and is referred to as the day 1 sample. The subsequent day 2 and day 3 blood samples were obtained at the time of routine morning blood collection done for clinical care. Blood was collected in EDTA tubes and centrifuged to separate plasma. Barcoded aliquots of plasma were stored at −80°C until biomarker measurement. No additives or protease inhibitors were added.
Biomarker measurements
Following one freeze-thaw cycle (storage at −80°C), IL-6 and IL-10 samples were analyzed on the Randox Evidence Investigator TM using a custom cytokine array developed by Randox Laboratories Ltd. (Crumlin, Northern Ireland, UK). The detection range for IL-6 and IL-10 is 0.6-790 and 0.9-840 pg/mL, respectively. The intra-assay coefficients of variation for IL-6 and IL-10 are 7 and 6 % for quality control (QC)1 and 7 and 3 % for QC2, respectively, and the inter-assay coefficients of variation are 16 and 17 % for QC1 and 14 and 9 % for QC2, respectively. We blinded the personnel measuring the biomarkers to clinical outcomes, and samples were analyzed according to the manufacturer's specifications. If a patient had insufficient plasma at a specific time point, the biomarker could not be measured and the patient was excluded from analyses for that time point.
Outcome definitions
The primary outcome, stage 2/3 AKI, was the development of at least stage 2 AKI, defined by Kidney Disease Improving Global Outcomes (KDIGO) [20] as at least a doubling of the serum creatinine level from the baseline preoperative value or receipt of acute dialysis, during the first postoperative week. The secondary outcome was Bany AKI^, which includes all patients diagnosed with at least stage 1 AKI (composite of stage 1, stage 2 and stage 3 AKI). Stage 1 AKI, defined by KDIGO, is a≥ 50 % increase in baseline serum creatinine concentration or a≥0.3 mg/dL increase in baseline serum creatinine concentration. We also analyzed resource utilization outcomes such as length of in-hospital stay, length of ICU stay, and time to extubation. Pre-and postoperative serum creatinine levels were measured in the same clinical laboratory for each patient at all sites.
Variable definitions
We collected preoperative characteristics, operative details, and postoperative complications using the definitions of the Society of Thoracic Surgeons [21] . We utilized the Risk Adjustment for Congenital Heart Surgery-1 (RACHS-1) consensus-based scoring system to categorize the complexity of surgery [22] . This method of risk stratification is a widely accepted tool for the evaluation of differences in outcomes of surgery for congenital heart disease. We determined the preoperative estimated glomerular filtration rate (eGFR) using the updated Schwartz equation [23] and determined eGFR percentiles based on published normal renal function data in children [24, 25] .
Statistical analysis
Continuous variables were compared with the two-sample t test or Wilcoxon rank sum test and dichotomous variables with the chi-squared test or Fisher's exact test. For the calculation of p values in Table 1 , we used one-way analysis of variance and Kruskal-Wallis tests, as appropriate, to compare continuous variables between multiple groups. To evaluate the association of each biomarker with AKI, we divided the cohort into tertiles on the basis of IL-6 or IL-10 levels. Mixed logistic regression models with random intercepts for each center were used to determine the adjusted odds ratios (OR) of AKI. Linear regression was used to evaluate the relationship between preoperative IL6 and postoperative tubular injury biomarkers [neutrophil gelatinase-associated lipocalin (NGAL), KIM-1, IL-18, L-FABP]. We adjusted for important covariates that predict AKI in the pediatric cardiac surgery setting, including age, gender, race, surgical site, RACHS-1, and CPB time. Poisson regression with log link function was used to estimate the association between biomarkers and clinical outcomes, including number of days to extubation, length of ICU stay, and length of hospital stay. Biomarker values below the assay's detectable limit were assigned the lower limit of detection.
Results

Characteristics of the study cohort
The characteristics of the 106 pediatric patients enrolled in the sub-study are listed in Table 1 by AKI status.
The median age of the participants of this cohort was 0.7 [interquartile range (IQR) 0.3-4.5] years; 58 % were male. All patients received CPB during cardiac surgery, with an average CPB time of 116 min and average cross-clamp time of 55 min. During their hospital stay, 56 (53 %) participants developed any AKI and 24 (23 %) participants developed stage 2/3 AKI. Two patients received acute dialysis, and two patients died before discharge.
Biomarker results and preoperative risk of AKI
Median preoperative plasma IL-6 concentrations were significantly higher in patients with stage 2/3 AKI (2.6 pg/mL, IQR 0.6-4.9 pg/mL) than in patients without stage 2/3 AKI (0.6 pg/mL, IQR 0.6-2.2 pg/mL) (p= 0.03). There was no significant difference in preoperat i v e p l a s m a I L -1 0 l e ve l s ( p = 0 . 8 ) [ E l e c t r o ni c Supplementary Material (ESM) Table 2 ]. Preoperative IL-6 and IL-10 levels in patients with any AKI versus those in patients with no AKI were not significantly different (ESM Table 1 ). Of note, 78 % of preoperative IL-10 values were undetectable by our laboratory assay.
Preoperative biomarker measurements were categorized into tertiles of IL-6 and IL-10 ( Table 2 ). Relative to the first tertile, the third tertile of IL-6 was significantly associated with a sixfold higher increased risk [95 % confidence interval (CI)1.16-35.35)] of stage 2/3 AKI after adjusting for age, gender, race, study site, RACH S-1 score, and CPB time. None of the preoperative tertiles of IL-10 were associated with stage 2/3 AKI.
Pre-operative IL-6 was also evaluated as a diagnostic test for predicting stage 2/3 AKI. The area under the curve (AUC) for preoperative IL-6 to predict stage 2/3 AKI was 0.69. The sensitivity and specificity of the third tertile of IL-6 (2.2 pg/ mL) was 0.63 and 0.76, respectively. Biomarker results and postoperative risk of AKI Plasma IL-6 and IL-10 concentrations, determined in blood samples collected within 6 h of arrival in the pediatric ICU (PICU), peaked at the first postoperative collection and then declined on day 3 (Fig. 1) . On day 3, plasma IL-6 concentration remained elevated, whereas the IL-10 concentration had returned to preoperative levels. AKI was most frequently diagnosed on day 2 after surgery [4] . On day 1, there was no statistically significant difference between patients with and without stage 2/3 AKI in terms of plasma IL-6 (p=0.4) and IL-10 (p=0.3) levels (ESM Table 2 ). On day 3, the median plasma IL-10 concentration was significantly higher in patients with stage 2/3 AKI (2.6 pg/mL, IQR 0.9-6.3 pg/mL) than in patients without stage 2/3 AKI (0.9 pg/mL, IQR 0.9-0.9 pg/mL) (p=0.001), and higher in patients with any AKI (0.9, pg/mL IQR 0.9-4.7 pg/mL) than in those with no AKI (0.9 pg/mL, IQR 0.9-0.9 pg/mL) (p= 0.02). Otherwise, IL-6 and IL-10 were not found to be significantly different in the AKI groups postoperatively. Of note, 68 % of day 3 IL-10 values were undetectable.
Biomarker results and nonrenal outcomes
The average lengths of stay in the PICU and hospital for the entire cohort were 5.5 [standard deviation (SD) 7.3] and 10 days (SD 9.9), respectively. The average length of mechanical ventilation for the entire cohort was 2.3 days (SD 1.6). Postoperatively, on day 3, plasma IL-6 concentration was linearly associated with a longer length of hospital stay (p= 0.0001). Otherwise, neither IL-6 nor IL-10 was significantly associated across all time points with the nonrenal outcomes of length of PICU stay, length of hospital stay, and length of mechanical ventilation. We were unable to reliably analyze associations with in-hospital mortality as there were only two deaths in this cohort.
Preoperative IL-6 and postoperative tubular biomarkers
Perioperative tubular injury biomarkers (NGAL, KIM-1, IL-18, L-FABP) were measured and described in this pediatric cardiac surgery cohort in previous studies [26, 27] . The relationship between preoperative IL-6 and postoperative tubular b IL-10 levels preoperative were undetectable in 78 % of the sample and are included in T1 data c IL-10 levels on day 3 were undetectable in 68 % of the sample and are included in T1 data biomarkers was statistically significant for NGAL on day 1, 2, and 3 and also for L-FABP on day 3. After multivariable adjustment, only day 1 NGAL concentration remained significantly associated with IL-6, with a R 2 of 0.13 (p=0.03) (ESM Table 3 ).
Discussion
In our multicenter study of children undergoing cardiac surgery with CPB, we have demonstrated for the first time that high levels of preoperative IL-6 are associated with AKI such that the children in the third tertile exhibited a sixfold increased risk of stage 2/3 AKI. Preoperative IL-6 concentration was also associated with tubular injury on day 1 such that there was a statistically significant relationship between pre-operative IL-6 concentration and day 1 NGAL level. We did not find an association between IL-10 and AKI except that IL-10 levels were still elevated on day 3 in patients who had AKI. We also found that on day 3, IL-6 level was associated with a prolonged stay in the hospital after surgery. This linear association on day 3 was statistically significant and stronger than that of serum creatinine concentration for predicting length of hospital stay [4] . To our surprise, there was only a weak correlation between the inflammatory biomarkers and CPB time compared with published reports in adults [28, 29] , suggesting that distinct pathways may mediate inflammation in children. This is the largest research study to examine perioperative IL-6 and IL-10 levels in children after cardiac surgery and their association with AKI. IL-6 is mainly secreted by lymphocytes, fibroblasts, macrophages, mesangial cells, and endothelial cells and plays a major role in regulating inflammatory and immunologic processes [30, 31] . IL-6 can also be upregulated and released from renal tubular epithelial cells in response to injury and plays a fundamental role in the pathophysiology of AKI [32] . Additionally, IL-6 production is increased by the myocardium in states of congestive heart failure, cardiac ischemia, and congenital heart disease [33] [34] [35] . Preoperatively, we found that IL-6 concentration was statistically different in patients who did and did not go on to develop stage 2/3 AKI. It is likely that IL-6 can serve as a marker for preoperative severity of illness, an ongoing inflammatory process, or cardiac dysfunction. These findings suggest that the timing of surgery and alleviation of inflammation before surgery may assist with reducing postoperative AKI. Alleviating preoperative inflammation may include treating any subclinical infection, heart failure, or myocardial dysfunction, and managing any systemic inflammatory process before surgery. Treating sources of inflammation may have been feasible in the pediatric cohort that we studied as 83 % of the patients' cardiac operations were considered to be elective.
Studies by Miklaszewska et al. [36] and Liu et al. [9] did not find a significant difference in IL-6 levels preoperatively, but these authors did report a significant difference in IL-6 levels postoperatively on the day of surgery in children with and without AKI. However, in another study, Morgan et al. [37] did not find any association between IL-6 level and AKI on the day after surgery, similar to our findings. There are likely multiple factors contributing to these differing results. One is the different AKI definition used by Miklaszewska et al. [36] , with AKI defined by a 25 % reduction in eGFR. In addition, Miklaszewska et al. [36] and Liu et al. [9] both measured IL-6 levels 2 h after bypass. Both of these studies showed the most substantial difference in IL-6 concentrations between AKI and non-AKI patients at this earliest time point after surgery, with the difference in IL-6 concentrations diminishing over time. In contrast, in our study, blood samples were collected within 6 h of bypass. Morgan et al. [37] also measured cytokine levels at a later time point of 4 h after surgery. In addition, different laboratory assays were used in these other studies to measure IL-6 levels. Given these inconsistencies, further research is required to evaluate IL-6, a central pro-inflammatory cytokine, as a candidate biomarker in AKI.
As an anti-inflammatory cytokine, IL-10 plays an important role in AKI. IL-10 limits inflammation and terminates inflammatory responses by decreasing the secretion of proinflammatory cytokines and inhibiting lymphocytes, dendritic cells, NK cells, and marcophages [38] . As a testament to its importance in the antiinflammatory pathway, several viral genomes, including those of Epstein-Barr virus, Cytomegalovirus, and herpes type 2 virus code for IL-10 homologs [39] . Additionally, several single nucleotide polymorphisms in the IL-10 promoter region have been associated with a faster decline in renal function in both immunoglobulin A nephropathy and focal segmental glomerulosclerosis [40] . Abnormally high or low levels of IL-10 have been shown to increase proteinuria and decrease GFR in animal models [39] , and IL-10 has also been shown to be elevated in several types of glomerulonephritides. Two previous studies which investigated IL-10 and its association with AKI reported mixed results [9, 12] . In the pediatric study by Liu et al. [9] , serum IL-10 level did not identify AKI on the day of surgery, and in the adult study on patients with septic shock by Payen et al. [12] , the serum IL-10 level on admission to the ICU was found to be associated with AKI. Postoperatively, we found that the IL-10 concentration was statistically different on day 3 in patients with and without AKI. We suspect that IL-10 is higher in children with AKI on day 3 in order to regulate a more pronounced inflammatory response at the tissue level. Another possibility is that IL-10 is a direct or indirect mediator of AKI [39] . While our IL-10 results are intriguing, we are most interested in a biomarker that predicts AKI before it is diagnosed by serum creatinine.
The roles IL-6 and IL-10 play in AKI are not entirely clear. Previous research indicates that cytokines have a direct role in the pathogenesis of AKI and are elevated in AKI states. There is also evidence that cytokines are cleared by the kidney and elevated when there is decreased renal function [41] . One pediatric study reported that impaired proximal tubule metabolism of IL-6 may be the cause of increases in both plasma and urine IL-6 [42] . However, the degree to which elevated cytokine levels are causing AKI or simply surrogate markers of decreased renal clearance has not yet been determined.
This study has a number of limitations. First, we lacked sufficient plasma volume to include all of the patients from our previously performed prospective study. A larger sample size would have improved our power to assess the performance of IL-6 and IL-10 in the perioperative setting. Another limitation was that we could not include oliguria as part of our AKI definition as we did not have an hourly record of urine output. Additionally, we were unable to evaluate mortality as an endpoint as there were only two deaths in this cohort. Finally, we used changes in serum creatinine to define AKI. Serum creatinine has limitations in its ability to estimate GFR, and we used it here to define the utility of IL-6 and IL-10. The strengths of our study include the prospective multicenter design and the known cause and time of AKI.
We have demonstrated that IL-6 and IL-10 concentrations increase substantially after cardiac bypass surgery in children. In addition, we have presented a novel finding in that IL-6 can preoperatively predict stage 2/3 AKI and may be a useful biomarker to plan the timing of surgery. Preoperative IL-6 levels may also help with the design of prevention clinical trials for AKI by enriching the patients who develop AKI after cardiac surgery. Future studies should further investigate the role of these biomarkers in the immediate postoperative period within 2 hours after surgery.
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